ENZY · Enzymatica AB (publ)
Market Cap
410.22M SEK
Shares
242.74M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Investor day
Close1.7800 SEK
Open1.7850 SEK
Day1.7100–1.7850 SEK
52W close1.6450–3.2000 SEK
Avg vol 30d86K
Last earningsOct 22, 2027
DataJan 2020–Oct 2026
Technicals
trend & momentum for long-term holders illustrative — not investment advicePrice context
position in its 52-week range
Range low 1.6450 SEK
Now 1.7800 SEK · 9%
Range high 3.2000 SEK
vs 200-day avg -19%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FNSE:ENZY | +2.9% | -15.2% | -36.9% | +4.1% | -6.3% |
Exchange listing
- Market
- FNSE
- Ticker
- ENZY
- ISIN
- SE0003943620
- Security
- —
- Trading currency
- SEK
Company
- Website
- https://enzymatica.com/
- Investor relations
- https://enzymatica.com/investors/the-share/
Other listings of this company
No other verified listings are available.
Recent dividends
No verified dividend payments are available for this listing yet.
Upcoming investor events
| Date | Event | Type |
|---|---|---|
| 2026-10-29 00:00 UTC | Interim report, Jan-Sep 2026 | Results publication |
| 2027-02-18 00:00 UTC | Year-end report, Jan-Dec 2026 | Results publication |
| 2027-04-28 00:00 UTC | Interim report Jan–Mar 2027 | Results publication |
| 2027-05-13 00:00 UTC | Annual General Meeting 2027 | Shareholder meeting |
| 2027-07-16 00:00 UTC | Interim report Apr–Jun 2027 | Results publication |
| 2027-10-22 00:00 UTC | Interim report Jul–Oct 2027 | Results publication |
Earnings calls
-
Earnings call · Q3 2027 2027-10-22 ScheduledInterim report Jul–Oct 2027
-
Earnings call · Q2 2027 2027-07-16 ScheduledInterim report Apr–Jun 2027
-
Annual General Meeting · May 2027 2027-05-13 ScheduledAnnual General Meeting 2027
-
Earnings call · Q1 2027 2027-04-28 ScheduledInterim report Jan–Mar 2027
-
Earnings call · Q4 2026 2027-02-18 ScheduledYear-end report, Jan-Dec 2026
-
Earnings call · Q3 2026 2026-10-29 ScheduledInterim report, Jan-Sep 2026